Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into the clinic, including candidates against Lyme disease and the chikungunya virus.
Valneva at a glance
Total revenues in 2021
Unique vaccine development programs
differentiated clinical and pre-clinical assets
robust commercial portfolio
on prevention of infectious diseases with significant unmet medical need
employees in six countries